Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical COLIRIOBCN070660 for moderately severe to severe non-proliferative diabetic retinopathy
2023-505791-30-01Phase 3Authorised
- Sponsor
- BCN Peptides
- Start
- Oct 2023
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic retinopathy (DR) comparing COLIRIOBCN070660 with Placebo COLIRIOBCN070660 (2 arms). Primary endpoint: Reduction or arrest of microvascular impairment. Planned start Oct 2023; status: authorised.
02
Drugs
COLIRIOBCN070660
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on 2023-505791-30-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505791-30-01.